Candiduria

A randomized, double-blind study of treatment with fluconazole and placebo

Jack D. Sobel, C. A. Kauffman, D. McKinsey, M. Zervos, Jose Antonio Vazquez, A. W. Karchmer, J. Lee, C. Thomas, H. Panzer, W. E. Dismukes, John H. Pottage, Gilbert J. Wise, Brian Simmons, Charles Cherubin, Susan Hadley, Douglas A. Holt, Daniel Hirsch, Melanie A. Fisher, Harry Gallis, Phillip Johnson & 9 others Brad Doebbeling, James Rahal, Richard Hamill, John Stern, Patricia K. Sharkey, Richard Mangi, Robert Rubin, Alan Sugar, Peter Pappas

Research output: Contribution to journalArticle

237 Citations (Scopus)

Abstract

Management of candiduria is limited by the lack of information about its natural history and lack of data from controlled studies on the efficacy of treating it with antimycotic agents. We compared fungal eradication rates among 316 consecutive candiduric (asymptomatic or minimally symptomatic) hospitalized patients treated with fluconazole (200 mg) or placebo daily for 14 days. In an intent-to-treat analysis, candiduria cleared by day 14 in 79 (50%) of 159 receiving fluconazole and 46 (29%) of 157 receiving placebo (P<.001), with higher eradication rates among patients completing 14 days of therapy (P<.0001), including 33 (52%) of 64 catheterized and 42 (78%) of 54 noncatheterized patients. Pretreatment serum creatinine levels were inversely related to candiduria eradication. Fluconazole initially produced high eradication rates, but cultures at 2 weeks revealed similar candiduria rates among treated and untreated patients. Oral fluconazole was safe and effective for short-term eradication of candiduria, especially following catheter removal. Long-term eradication rates were disappointing and not associated with clinical benefit.

Original languageEnglish (US)
Pages (from-to)19-24
Number of pages6
JournalClinical Infectious Diseases
Volume30
Issue number1
DOIs
StatePublished - Feb 7 2000

Fingerprint

Fluconazole
Double-Blind Method
Placebos
Therapeutics
Natural History
Creatinine
Catheters
Serum

ASJC Scopus subject areas

  • Microbiology (medical)
  • Infectious Diseases

Cite this

Sobel, J. D., Kauffman, C. A., McKinsey, D., Zervos, M., Vazquez, J. A., Karchmer, A. W., ... Pappas, P. (2000). Candiduria: A randomized, double-blind study of treatment with fluconazole and placebo. Clinical Infectious Diseases, 30(1), 19-24. https://doi.org/10.1086/313580

Candiduria : A randomized, double-blind study of treatment with fluconazole and placebo. / Sobel, Jack D.; Kauffman, C. A.; McKinsey, D.; Zervos, M.; Vazquez, Jose Antonio; Karchmer, A. W.; Lee, J.; Thomas, C.; Panzer, H.; Dismukes, W. E.; Pottage, John H.; Wise, Gilbert J.; Simmons, Brian; Cherubin, Charles; Hadley, Susan; Holt, Douglas A.; Hirsch, Daniel; Fisher, Melanie A.; Gallis, Harry; Johnson, Phillip; Doebbeling, Brad; Rahal, James; Hamill, Richard; Stern, John; Sharkey, Patricia K.; Mangi, Richard; Rubin, Robert; Sugar, Alan; Pappas, Peter.

In: Clinical Infectious Diseases, Vol. 30, No. 1, 07.02.2000, p. 19-24.

Research output: Contribution to journalArticle

Sobel, JD, Kauffman, CA, McKinsey, D, Zervos, M, Vazquez, JA, Karchmer, AW, Lee, J, Thomas, C, Panzer, H, Dismukes, WE, Pottage, JH, Wise, GJ, Simmons, B, Cherubin, C, Hadley, S, Holt, DA, Hirsch, D, Fisher, MA, Gallis, H, Johnson, P, Doebbeling, B, Rahal, J, Hamill, R, Stern, J, Sharkey, PK, Mangi, R, Rubin, R, Sugar, A & Pappas, P 2000, 'Candiduria: A randomized, double-blind study of treatment with fluconazole and placebo', Clinical Infectious Diseases, vol. 30, no. 1, pp. 19-24. https://doi.org/10.1086/313580
Sobel, Jack D. ; Kauffman, C. A. ; McKinsey, D. ; Zervos, M. ; Vazquez, Jose Antonio ; Karchmer, A. W. ; Lee, J. ; Thomas, C. ; Panzer, H. ; Dismukes, W. E. ; Pottage, John H. ; Wise, Gilbert J. ; Simmons, Brian ; Cherubin, Charles ; Hadley, Susan ; Holt, Douglas A. ; Hirsch, Daniel ; Fisher, Melanie A. ; Gallis, Harry ; Johnson, Phillip ; Doebbeling, Brad ; Rahal, James ; Hamill, Richard ; Stern, John ; Sharkey, Patricia K. ; Mangi, Richard ; Rubin, Robert ; Sugar, Alan ; Pappas, Peter. / Candiduria : A randomized, double-blind study of treatment with fluconazole and placebo. In: Clinical Infectious Diseases. 2000 ; Vol. 30, No. 1. pp. 19-24.
@article{bb48302897dc45d8bdfc2935de77fe5f,
title = "Candiduria: A randomized, double-blind study of treatment with fluconazole and placebo",
abstract = "Management of candiduria is limited by the lack of information about its natural history and lack of data from controlled studies on the efficacy of treating it with antimycotic agents. We compared fungal eradication rates among 316 consecutive candiduric (asymptomatic or minimally symptomatic) hospitalized patients treated with fluconazole (200 mg) or placebo daily for 14 days. In an intent-to-treat analysis, candiduria cleared by day 14 in 79 (50{\%}) of 159 receiving fluconazole and 46 (29{\%}) of 157 receiving placebo (P<.001), with higher eradication rates among patients completing 14 days of therapy (P<.0001), including 33 (52{\%}) of 64 catheterized and 42 (78{\%}) of 54 noncatheterized patients. Pretreatment serum creatinine levels were inversely related to candiduria eradication. Fluconazole initially produced high eradication rates, but cultures at 2 weeks revealed similar candiduria rates among treated and untreated patients. Oral fluconazole was safe and effective for short-term eradication of candiduria, especially following catheter removal. Long-term eradication rates were disappointing and not associated with clinical benefit.",
author = "Sobel, {Jack D.} and Kauffman, {C. A.} and D. McKinsey and M. Zervos and Vazquez, {Jose Antonio} and Karchmer, {A. W.} and J. Lee and C. Thomas and H. Panzer and Dismukes, {W. E.} and Pottage, {John H.} and Wise, {Gilbert J.} and Brian Simmons and Charles Cherubin and Susan Hadley and Holt, {Douglas A.} and Daniel Hirsch and Fisher, {Melanie A.} and Harry Gallis and Phillip Johnson and Brad Doebbeling and James Rahal and Richard Hamill and John Stern and Sharkey, {Patricia K.} and Richard Mangi and Robert Rubin and Alan Sugar and Peter Pappas",
year = "2000",
month = "2",
day = "7",
doi = "10.1086/313580",
language = "English (US)",
volume = "30",
pages = "19--24",
journal = "Clinical Infectious Diseases",
issn = "1058-4838",
publisher = "Oxford University Press",
number = "1",

}

TY - JOUR

T1 - Candiduria

T2 - A randomized, double-blind study of treatment with fluconazole and placebo

AU - Sobel, Jack D.

AU - Kauffman, C. A.

AU - McKinsey, D.

AU - Zervos, M.

AU - Vazquez, Jose Antonio

AU - Karchmer, A. W.

AU - Lee, J.

AU - Thomas, C.

AU - Panzer, H.

AU - Dismukes, W. E.

AU - Pottage, John H.

AU - Wise, Gilbert J.

AU - Simmons, Brian

AU - Cherubin, Charles

AU - Hadley, Susan

AU - Holt, Douglas A.

AU - Hirsch, Daniel

AU - Fisher, Melanie A.

AU - Gallis, Harry

AU - Johnson, Phillip

AU - Doebbeling, Brad

AU - Rahal, James

AU - Hamill, Richard

AU - Stern, John

AU - Sharkey, Patricia K.

AU - Mangi, Richard

AU - Rubin, Robert

AU - Sugar, Alan

AU - Pappas, Peter

PY - 2000/2/7

Y1 - 2000/2/7

N2 - Management of candiduria is limited by the lack of information about its natural history and lack of data from controlled studies on the efficacy of treating it with antimycotic agents. We compared fungal eradication rates among 316 consecutive candiduric (asymptomatic or minimally symptomatic) hospitalized patients treated with fluconazole (200 mg) or placebo daily for 14 days. In an intent-to-treat analysis, candiduria cleared by day 14 in 79 (50%) of 159 receiving fluconazole and 46 (29%) of 157 receiving placebo (P<.001), with higher eradication rates among patients completing 14 days of therapy (P<.0001), including 33 (52%) of 64 catheterized and 42 (78%) of 54 noncatheterized patients. Pretreatment serum creatinine levels were inversely related to candiduria eradication. Fluconazole initially produced high eradication rates, but cultures at 2 weeks revealed similar candiduria rates among treated and untreated patients. Oral fluconazole was safe and effective for short-term eradication of candiduria, especially following catheter removal. Long-term eradication rates were disappointing and not associated with clinical benefit.

AB - Management of candiduria is limited by the lack of information about its natural history and lack of data from controlled studies on the efficacy of treating it with antimycotic agents. We compared fungal eradication rates among 316 consecutive candiduric (asymptomatic or minimally symptomatic) hospitalized patients treated with fluconazole (200 mg) or placebo daily for 14 days. In an intent-to-treat analysis, candiduria cleared by day 14 in 79 (50%) of 159 receiving fluconazole and 46 (29%) of 157 receiving placebo (P<.001), with higher eradication rates among patients completing 14 days of therapy (P<.0001), including 33 (52%) of 64 catheterized and 42 (78%) of 54 noncatheterized patients. Pretreatment serum creatinine levels were inversely related to candiduria eradication. Fluconazole initially produced high eradication rates, but cultures at 2 weeks revealed similar candiduria rates among treated and untreated patients. Oral fluconazole was safe and effective for short-term eradication of candiduria, especially following catheter removal. Long-term eradication rates were disappointing and not associated with clinical benefit.

UR - http://www.scopus.com/inward/record.url?scp=0141611043&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0141611043&partnerID=8YFLogxK

U2 - 10.1086/313580

DO - 10.1086/313580

M3 - Article

VL - 30

SP - 19

EP - 24

JO - Clinical Infectious Diseases

JF - Clinical Infectious Diseases

SN - 1058-4838

IS - 1

ER -